Skip to main content

Table 2 Administration of levosimendan or placebo

From: Prophylactic use of levosimendan in pediatric patients undergoing cardiac surgery: a prospective randomized controlled trial

Variable

Levosimendan group (n = 94)

Placebo group (n = 93)

p value

Time of infusion started after surgery (h)

2.27 ± 0.81

2.39 ± 0.81

0.453

Interruption of infusion due to adverse events, n (%)

6 (6.4%)

5 (5.4%)

0.770

Duration of infusion, n (%)

 < 24

3 (3.2%)

2 (2.2%)

0.659

 24–48

8 (8.5%)

5 (5.4%)

0.399

 48

83 (88.3%)

86 (92.5%)

0.333

  1. Data are means ± standard deviation (SD) for continuous variables and number of subjects (n) and percentage (%)for categorical variables
Back to article page

Critical Care

ISSN: 1364-8535